E-POSTER PROGRAMME
SUNDAY
19
SEPTEMBER
Chairs: C. Denis (France)
16:30
PO 21 VON WILLEBRAND DISEASE
Liver gene therapy with lentiviral vectors corrects hemophilia A in mice and achieves normal-range factor VIII activity in non-human primates
M. Milani (Italy)
16:40
PO 23 VON WILLEBRAND DISEASE
Differential release of von Willebrand factor and von Willebrand factor propeptide from platelet alpha granules
M. Swinkels (The Netherlands)
16:50
PO 24 VON WILLEBRAND DISEASE
Genetic characterization of von Willebrand disease type 2 in Milan cohort patients
O. Seidizadeh (Italy)
17:00
PO 25 VON WILLEBRAND DISEASE
Identification of small interfering RNAs for allele-selective silencing of murine von Willebrand factor
Y. Jongejan (The Netherlands)
17:10
PO 26 VON WILLEBRAND DISEASE
Evaluation of health-related quality of life in patients with von Willebrand disease on long term prophylaxis: WiSH QoL intermediary results
A. Borel-Derlon (France)
17:20
PO 22 VON WILLEBRAND DISEASE
Genetic determination of enhanced von Willebrand factor clearance
O. Seidizadeh (Italy)
Chairs: S. Lacroix-Desmazes (France)
16:30
PO 27 VARIOUS
PAD4-mediated citrullination in sepsis and immune Thrombotic Thrombocytopenic Purpura
T. Arfman (The Netherlands)
16:40
PO 29 VARIOUS
The extracellular protease EpiP from S. aureus triggers blood coagulation by proteolytically activating prothrombin (ProT) and platelet protease activated receptor 1
V. De Filippis (Italy)
16:50
PO 30 VARIOUS
Exploring the role of factor VIII as a potential player in cancer cells
A. Follenzi (Italy)
17:00
PO 31 VARIOUS
Transplacental delivery of recombinant Fc-fused factor VIII (rFVIIIFc) in FVIII-deficient mice
A. Reyes-Ruiz (France)
17:10
PO 28 VARIOUS
Interaction of factor XI with ligands studied with novel anti-factor XI nanobodies
A. Bar Barroeta (The Netherlands)
17:20
POSSIBLE REPEAT TIME
Chairs: J. Voorberg (The Netherlands)
16:30
PO 09 LABORATORY METHODS
The specificity of the assay determines the measurement of FVIII antigen levels in patients with severe haemophilia A
M. Jacquemin (Belgium)
16:40
PO 10 LABORATORY METHODS
Evaluation of the different platelet-dependent von Willebrand factor activity assays capacity to assess the in vivo inhibitory effect of caplacizumab on the VWF-platelet interaction
L. Baronciani (Italy)
16:50
PO 11 LABORATORY METHODS
Measurement of von Willebrand factor levels via fiber optic-surface plasmon resonance
B. Calcoen (Belgium)
17:00
POSSIBLE REPEAT TIME